BAFNAPH Stock View

Bafna Pharmaceuticals Ltd
stock-view-header

₹ 90

icon -0.90 | -0.99
Market Cap ₹( Cr.)
2,129.07
Proj. P/E (x)
Proj. P/BV (x)
Proj. ROE (%)
Proj EV / EBITDA (x)
--
Proj. Revenue ( Cr.)

Stock View

Last Updated On.
18-Feb-2024
 

The average score for Bafna Pharmaceuticals Ltd stands at 5 against 4, three months back.

Bafna Pharmaceuticals Limited is an India-based company, which is engaged in the manufacture of drugs and medicines and selling a reputed brand namely RARICAP. The Company caters to both domestic and international market. It operates in generic pharmaceutical segment. The Company manufactures 336 licensed pharmaceutical formulations and have globally registered 78 of its products. It supplies its products to the United Kingdom, Europe, and Australian markets. The Company's Grantlyon facility has the capability to supply both small-scale clinical trial quantities and commercial-scale requirements. The Company’s subsidiary is Bafna Lifestyles Remedies Limited.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.


Technical Data

50 DMA(₹)
97.58
100 DMA(₹)
93.16
200 DMA(₹)
93.06
52 Weeks Range
78.51     125.55

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required